Medicare Will Cover PET To Distinguish Alzheimer’s From Other Dementia
This article was originally published in The Gray Sheet
Executive Summary
CMS' decision to provide national coverage of FDG-PET imaging for some suspected dementia patients corresponds with the Neuroimaging Work Group of the Alzheimer's Association's consensus position
You may also be interested in...
CMS Could Use Higher Co-Pays To Control Technology Utilization – Tunis
Higher co-pays and only partial coverage for technologies lacking strong evidence of benefit and cost-effectiveness could better control utilization, according to CMS Chief Medical Officer Sean Tunis, MD
CMS Could Use Higher Co-Pays To Control Technology Utilization – Tunis
Higher co-pays and only partial coverage for technologies lacking strong evidence of benefit and cost-effectiveness could better control utilization, according to CMS Chief Medical Officer Sean Tunis, MD
CMS gives thumbs-up to PET/Alzheimer’s coverage
Final decision memo aligns with draft decision to cover the scans in a practical clinical trial and for differentiating between Alzheimer's disease and fronto-temporal dementia in patients that have been evaluated for other causes of dementia and still have uncertain clinical symptoms (1"The Gray Sheet" June 24, 2004, p. 6). The national coverage decision is the first reviewed under Medicare Modernization Act requirements for a draft decision posting followed by a 30-day comment period, and implementation of a final policy within 90 days of posting a final decision memo...